Summit Therapeutics (SMMT) Ends 2025 With Strong Cash Reserves and Increased Clinical Investment [Yahoo! Finance]
Summit Therapeutics Inc. (SMMT)
Last summit therapeutics inc. earnings: 6/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
summitplc.com/investors/investor-centre
Company Research
Source: Yahoo! Finance
for 2025 with a strong financial foundation, reporting ~$713.4 million in cash and no outstanding debt. While GAAP operating expenses for Q4 reached $225 million, this represented a decrease from the previous quarter. Conversely, non-GAAP operating expenses rose to $113.3 million as the company ramped up investment in its Harmony 3 and Harmony 7 clinical trials. The company's focus remains on the development of ivonescimab, supported by a pipeline of 15 Phase 3 trials and over 4,000 enrolled patients globally. A key highlight is the upcoming interim progression-free survival analysis for the Harmony 3 squamous lung cancer cohort, expected in Q2 2026. Summit also expanded its therapeutic reach through high-profile clinical collaborations, including a partnership with GSK to evaluate ivonescimab alongside a novel antibody-drug conjugate and a collaboration with Revolution Medicines to test combinations with RAS inhibitors across various solid tumors. Summit Therapeutics (SMMT) Ends
Show less
Read more
Impact Snapshot
Event Time:
SMMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SMMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SMMT alerts
High impacting Summit Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
SMMT
News
- Summit Therapeutics Inc. (SMMT) Presents at TD Cowen 46th Annual Health Care Conference Transcript [Seeking Alpha]Seeking Alpha
- Summit Therapeutics Inc. (SMMT) Focused on Non-Small Cell Lung Cancer Trial of Ivonescimab [Yahoo! Finance]Yahoo! Finance
- Summit Therapeutics to Present at Upcoming Investor ConferencesBusiness Wire
- Summit Therapeutics Inc (SMMT) Q4 2025 Earnings Call Highlights: Strong Cash Position and ... [Yahoo! Finance]Yahoo! Finance
- Summit Therapeutics Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]Yahoo! Finance
SMMT
Earnings
- 2/23/26 - Beat
SMMT
Sec Filings
- 2/23/26 - Form S-8
- 2/23/26 - Form 10-K
- 2/23/26 - Form 8-K
- SMMT's page on the SEC website